Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial
Xenofon Baraliakos, Laura Coates, Laure Gossec et. al.

Nov 13th, 2019 - Background/Purpose: Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis1. Evidence is limited on the efficacy of biologics in the treatment of patients (pts) with PsA having axial manifestations that affect between 30–70% of pts2, particularly as validated classification criteria for this s...

Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naïve Psoriatic Ar...
Elsa Vieira-Sousa, Pedro Alves, Ana Maria Rodrigues et. al.

Nov 13th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) dactylitis is associated with an increased risk of erosions and higher disease activity. Dactylitis treatment strategies are however controversial due to the absence of evidence from randomized controlled trials studying dactylitis as a primary outcome. The objective of this trial was to assess the efficacy of golimumab in combination with methotrex...

Efficacy and Safety of Low-dose IL-2 in Rebuilting Immunity Re-equilibrium of Psoriatic Arthritis Patients
Jia Wang, Yu-fei Hao, Sheng-xiao Zhang et. al.

Nov 13th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) is a T lymphocytes-mediated inflammatory condition. Although regulatory T cells (Tregs) isolated from blood and psoriatic skin have been showed a functional deficiency in suppressing effector T-cells in PsA, absolute quantitative status of peripheral Treg or Th17 cells is still unclear. On the other hand, recent studies have revealed that low-dose I...

Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in P...
Philip Mease, Saima Chohan, Ferran J. García Fructuoso et. al.

Nov 13th, 2019 - Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe plaque psoriasis treatment and is under investigation for PsA. This study evaluated the 24-week efficacy and safety results from a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b TIL study in patients with active PsA (NCT02980692). Methods...

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Contro...
Philip Mease, Laure Gossec, Laura Coates et. al.

Nov 13th, 2019 - Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of significant inflammatory disease activity’.1,2 Since many patients with PsA may not achieve clinical remission, treatment recommendations recognise minimal or low disease activity as an important alternative treatment t...

PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis
Ana-Maria Orbai, Rebecca Manno, Jamie Perin et. al.

Nov 12th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) symptoms and quality of life are core domains for PsA assessment1. The PROMIS Profile29 measures symptoms and quality of life using a T-score metric referenced to the general population, and has not been used in PsA before. The objective was to assess construct validity of the PROMIS Profile29 in PsA. Methods: Participants with PsA were followed eve...

Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
W. Benjamin Nowell, Elaine Karis, Kelly Gavigan et. al.

Nov 12th, 2019 - Background/Purpose: Methotrexate (MTX) is a frequently used therapy in both Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) due to its beneficial effects in both populations. Despite the well-known benefits of MTX, it is associated with a number of potential side effects and tolerability issues including nausea and fatigue, gastrointestinal toxicity, skin reactions, headaches, mouth sor...

Pain and Anxiety Are Independent Factors Associated to Sleep Impairment in Psoriatic Arthritis: A Multicentric Study in 14 Countries
Penelope Palominos, Laura Coates, Charles Kohem et. al.

Nov 12th, 2019 - Background/Purpose: Sleep quality is diminished in patients with psoriatic arthritis (PsA) and close to 40% of PsA patients consider sleep impairment a priority domain.This work analyzed determinants of impaired sleep in patients with PsA. Methods: This was a cross-sectional analysis of an observational study (ReFlap, NCT03119805), which included adult patients with definite PsA with ≥ 2 years ...

MDA Versus DAPSA: Applicability in a Real World
rafaela Gonçalves, Lays Martins, henrique mariz et. al.

Nov 12th, 2019 - Background/Purpose: Background/Purpose: Psoriatic arthritis (PsA) is a progressive, chronic, and potentially irreversible inflammatory disorder. Systematic clinical follow-up of PsA patients is necessary to maintain and adjusting the proposed therapy. There are two different disease activity composite index suggested by Treat To Target (1). MDA (2) defines a state of illness and includes joint ...

Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results
Clara Pérez-Velásquez, Oihane Ibarguengoitia-Barrena, David Montero-Seisdedos et. al.

Nov 12th, 2019 - Background/Purpose: The multidisciplinary unit of psoriatic arthritis (PsA) are attractive to improve the early diagnosis and optimize the management of complex patients with PsA. There are published data about different models, activity data and patient satisfaction in this kind os unit. To evaluate its effectiveness, we also need to know the clinical results of patients with PsA who visit the...

Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie, Mei Liu, Meghan Glynn et. al.

Nov 12th, 2019 - Background/Purpose: Oligoarticular PsA accounts for ≈50% of PsA worldwide, but only a paucity of data describes disease burden among these patients. The Corrona PsA/SpA Registry, a prospective, US-based, observational cohort study, collects real-world data on PsA patient characteristics and treatment, including oligoarthritis. This analysis characterized patient demographics, clinical character...

Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis
Ana-Maria Orbai, Jamie Perin, Albert W Wu et. al.

Nov 12th, 2019 - Background/Purpose: Pain, physical function and fatigue are outcomes reported as having the greatest importance to people with psoriatic arthritis (PsA)1,2. We assessed these outcomes in participants in a longitudinal PsA study using Patient Reported Outcomes Measurement Information System (PROMIS) measures, which have not been used before in PsA, concomitantly with measures of PsA-specific dis...

The Paradoxical Effect of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center
Rebecca Haberman, Samrachana Adhikari, Deborah Ramirez et. al.

Nov 12th, 2019 - Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous inflammatory disease affecting skin, joints, and other domains. While psychiatric diseases (i.e., depression and anxiety) are known comorbidities, little is known about their impact on disease severity and patient reported outcomes (PROs). The objective of this study was to characterize the prevalence of psychiatric comorbidities i...

Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study
Jennifer Belasco, Sandra Garcet, Mustimbo roberts et. al.

Nov 12th, 2019 - Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, has been shown to improve disease activity in patients with psoriatic arthritis (PsA), but its effect on psoriatic inflammation at a molecular level has not been determined. Methods: 40 patients received ABA and 38 received PBO in this substudy of a 24 week, Phase 3, randomized, double blind, placebo (PBO) control...

Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Alexis Ogdie, Ervant Maksabedian, Bradley Stolshek et. al.

Nov 12th, 2019 - Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA).  One recent study has identified shorter MTX persistence among patients with PsA compared to RA in the US,1 while another study in Europe found similar persistence on MTX in RA and PsA.2 In addition, tolerability to MTX m...

Assessing Risk of PsA Progression: Results from a Combined Psoriasis-PsA Center Cohort
Rebecca Haberman, Samrachana Adhikari, Deborah Ramirez et. al.

Nov 12th, 2019 - Background/Purpose: About 30% of patients with skin psoriasis (PsO) develop psoriatic arthritis (PsA). The reasons for why only some progress to synovio-enthesial disease from skin involvement remains unknown. Genetic, environmental and clinical-demographic factors have been implicated, but are yet to be characterized in specialized, combined care centers. We aim to describe clinical phenotypes...

Unmet Treatment Needs in Patients with Psoriatic Arthritis
Daniel Aletaha, Mihalina Georgallis, Matthew Wallace et. al.

Nov 12th, 2019 - Background/Purpose: Despite significant advances in the treatment of psoriatic arthritis (PsA), disease control and remission remain a challenge. Research characterizing residual disease burden with current therapies and identifying unmet treatment needs across clinical, patient-focused, and economic domains has been limited. The aim of this review is to establish unmet needs in PsA patients wi...

A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis
Mehmet Tuncay Duruoz, Halise Hande Gezer, Kemal Nas et. al.

Nov 12th, 2019 - Background/Purpose: This study sought to compare the disease activity and its relationship with anxiety, depression, fatigue, and fibromyalgia of patients with psoriatic arthritis (PsA) between female and male gender in a Turkish population. Methods: This multi-center Turkish League Against Rheumatism (TLAR) Network study included 1134 patients (726 females, 408 males) diagnosed with PsA accord...

Validation of the Modified Stokes Ankylosing Spondylitis Spinal Score (mSASSS) as a Tool to Assess Axial PsA
Daniel Pau, Justine (Yang) Ye, Sevket Tunc et. al.

Nov 12th, 2019 - Background/Purpose: Axial joint involvement commonly links psoriatic arthritis (PsA) to spondyloarthritis with widely variable prevalence (25-70%). Patients with axial PsA (AxPsA) are older than patients with ankylosing spondylitis (AS) and identifying radiographic changes related to the spondylitis may be more challenging leading to disagreement among readers. Currently, there is no universall...

Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis
Diego Benavent, Chamaida Plasencia, Victoria Navarro-Compán et. al.

Nov 12th, 2019 - Background/Purpose: Assessment of the disease in psoriatic arthritis (PsA) remains a clinical challenge. Hence, there is no agreement on which index best correlates with the actual disease state of patients. Objective: to assess the performance of and agreement between composite activity indices of common use in clinical practice (DAPSA and DAS66) and the physician global assessment (PhGA) to e...